Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320202 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2GPR119HPGDALOX15 | |
| SCHEMBL27302816 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2SCD5GPR119HDAC1 | |
| SCHEMBL28587906 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2HPGDALOX15TSHR | |
| SCHEMBL22323275 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2SCD5HDAC2HPGD | |
| SCHEMBL1086226 | 0.79 | USP2 (0.47) | USP2SMN1; SMN2GPR119HPGDALOX15 | |
| SCHEMBL31191651 | 0.79 | USP2 (0.42) | USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL346995 | 0.78 | USP2 (0.56) | USP2SMN1; SMN2GPR119ACACBHPGD | |
| SCHEMBL20658557 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2GPR119HPGDALOX15 | |
| SCHEMBL15268805 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2GPR119HPGDALOX15 | |
| SCHEMBL20423343 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2GPR119HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | USP2 4178/4885SMN1; SMN2 4491/4885SCD5 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.